Syapse Inc.
Syapse Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Syapse Inc..
Syapse Inc. is a company.
Key people at Syapse Inc..
Syapse Inc. is a healthcare technology company that developed a Precision Medicine Platform integrating clinical and genomic data to deliver actionable insights, primarily for oncology care. It serves healthcare providers, academic and community health systems, and partners with pharma companies like Amgen and Pfizer to improve patient outcomes through real-world evidence, focusing on cancer diagnostics via NGS (next-generation sequencing) informatics applications such as Syapse Oncology, Syapse MDx, and Syapse PGx.[1][2][3] The platform supports end-to-end workflows from patient sample processing to physician reports, enabling precision medicine implementation at the point of care.[1][3] Syapse raised $204.5M before being acquired by N-Power Medicine in December 2024, expanding community-based oncology research networks with over 1,000 oncologists.[2][4]
Founded in 2008 in San Francisco, California, Syapse (formerly BDLicense) emerged to address gaps in precision oncology by developing informatics for NGS-based diagnostics.[1][2] The company built its Precision Medicine Platform as a comprehensive software suite for health systems, gaining early traction through partnerships with major pharma firms and recognition for transforming real-world data into clinical insights.[1][3] Key milestones include marketing specialized NGS applications and expanding to key markets like the U.S., South Korea, and Japan, culminating in its acquisition by N-Power Medicine in December 2024 to bolster community oncology trials.[1][2][4]
Syapse rides the precision medicine trend in oncology, leveraging AI and real-world evidence to personalize treatments amid rising NGS adoption and demand for community-based care.[2][3][4] Its timing aligns with market forces like expanding clinical trials, pharma needs for diverse patient data, and shifts toward decentralized research, where community oncologists (serving most patients) drive faster drug development.[4] By integrating with N-Power Medicine, Syapse influences the ecosystem by scaling "always-on" prospective trials, bridging academic tools with community settings to democratize access to innovations and boost trial participation.[4]
Post-acquisition, Syapse's platform will fuse with N-Power's AI-driven registry and support model to supercharge community oncology trials, potentially reaching millions more patients.[4] Trends like AI-enhanced real-world data and regulatory pushes for diverse trials will propel growth, evolving its role from platform provider to core enabler of faster oncology drug delivery.[2][4] This positions the combined entity to redefine precision care, tying back to Syapse's mission of extinguishing disease burdens through data-powered, collaborative impact.[1][4]
Key people at Syapse Inc..
